Implications of Recent Clinical Trials on Pay-for-Performance

Published in: American journal of health-system pharmacy, v. 66, no. 9, May 2009, p. 864-867

Posted on on January 01, 2009

by Walid F. Gellad, Allan S. Detsky, Niteesh K. Choudhry

Ideally pay-for-performance in chronic diseases would be based on outcomes that really matter to patients, such as death, morbidity, and disability. Instead, many of the quality metrics used in pay-for-performance address process measures (e.g., the percentage of diabetic patients who receive glycosylated hemoglobin [HbA1c] testing or a lipid profile each year). The few measures that attempt to address clinical outcomes actually measure surrogate markers like HbA1c, low-density-lipoprotein (LDL) cholesterol, and blood pressure.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.